vs
Side-by-side financial comparison of Almonty Industries Inc. (ALM) and LENZ Therapeutics, Inc. (LENZ). Click either name above to swap in a different company.
LENZ Therapeutics, Inc. is the larger business by last-quarter revenue ($12.5M vs $6.3M, roughly 2.0× Almonty Industries Inc.). Almonty Industries Inc. runs the higher net margin — -86.1% vs -133.6%, a 47.5% gap on every dollar of revenue.
Almonty Industries Inc. is an international mining company primarily engaged in the extraction and development of tungsten resources. The company operates in Spain, Portugal, and South Korea and is publicly traded on the Toronto Stock Exchange (TSX). The current Chief Executive Officer is Lewis Black.
LENZ Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing novel ophthalmic therapies. Its lead product candidates address presbyopia, the age-related loss of near vision, catering to global patient groups with unmet medical needs in the eye care sector.
ALM vs LENZ — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.3M | $12.5M |
| Net Profit | $-5.4M | $-16.7M |
| Gross Margin | — | — |
| Operating Margin | — | -151.1% |
| Net Margin | -86.1% | -133.6% |
| Revenue YoY | — | — |
| Net Profit YoY | — | -63.5% |
| EPS (diluted) | — | $-0.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $6.3M | $12.5M | ||
| Q2 25 | $7.2M | $5.0M | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 |
| Q3 25 | $-5.4M | $-16.7M | ||
| Q2 25 | $-58.2M | $-14.9M | ||
| Q3 24 | — | $-10.2M | ||
| Q2 24 | — | $-10.3M |
| Q3 25 | — | -151.1% | ||
| Q2 25 | — | -337.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | -86.1% | -133.6% | ||
| Q2 25 | -809.4% | -298.2% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | $-0.59 | ||
| Q2 25 | — | $-0.53 | ||
| Q3 24 | — | $-0.38 | ||
| Q2 24 | — | $-0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $25.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $193.9M |
| Total Assets | — | $210.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $25.4M | ||
| Q2 25 | — | $37.6M | ||
| Q3 24 | — | $41.0M | ||
| Q2 24 | — | $84.0M |
| Q3 25 | — | $193.9M | ||
| Q2 25 | — | $206.4M | ||
| Q3 24 | — | $215.3M | ||
| Q2 24 | — | $192.9M |
| Q3 25 | — | $210.7M | ||
| Q2 25 | — | $217.3M | ||
| Q3 24 | — | $224.0M | ||
| Q2 24 | — | $202.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-8.6M |
| Free Cash FlowOCF − Capex | — | $-9.0M |
| FCF MarginFCF / Revenue | — | -72.2% |
| Capex IntensityCapex / Revenue | — | 3.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-47.5M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | $-8.6M | ||
| Q2 25 | — | $-11.5M | ||
| Q3 24 | — | $-10.6M | ||
| Q2 24 | — | $-15.8M |
| Q3 25 | — | $-9.0M | ||
| Q2 25 | — | $-11.7M | ||
| Q3 24 | — | $-10.8M | ||
| Q2 24 | — | $-15.9M |
| Q3 25 | — | -72.2% | ||
| Q2 25 | — | -235.0% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q3 25 | — | 3.5% | ||
| Q2 25 | — | 4.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
